Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury.

ABSTRACT: Acute respiratory distress syndrome is a major cause of respiratory failure in critically ill patients. Despite extensive research into its pathophysiology, mortality remains high. No effective pharmacotherapy exists. Based largely on numerous preclinical animal studies, administration of mesenchymal stem or stromal cell (MSC) as a therapeutic for acute lung injury (ALI) holds great promise, and Phase I and II clinical trials are currently under way internationally. However, concern for the use of stem cells, specifically the risk of iatrogenic tumor formation, as well as the prohibitive cost of production, storage, and distribution of cells in bone marrow transplant facilities, may limit access to this lifesaving therapy. Accumulating evidence now suggest that novel stem cell-derived ther

SUBMITTER: Lee JH 

PROVIDER: S-EPMC6368889 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature